Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
SkinBioTherapeutics ( (GB:SBTX) ) just unveiled an announcement.
SkinBioTherapeutics plc, a life science company specialising in skin health technologies and products, develops cosmetic skincare actives through its SkinBiotix® platform and gut-skin axis food supplements under the AxisBiotix™ brand, supported by retail and e-commerce distribution. Through partnerships, including with Croda for Zenakine™, and acquisitions that add manufacturing and geographic reach, the company is building a vertically integrated skin healthcare portfolio from its Newcastle base.
The company announced that CEO Stuart Ashman has resigned following his suspension pending an investigation into matters related to his conduct, with a full inquiry underway supported by external professional advisers. Non-Executive Chairman Martin Hunt has stepped in as Executive Chairman on an interim basis while the board launches a search for both an interim and a permanent chief executive, a leadership transition that introduces near-term uncertainty but is designed to maintain operational continuity and reassure markets and shareholders about governance standards.
The most recent analyst rating on (GB:SBTX) stock is a Hold with a £19.50 price target. To see the full list of analyst forecasts on SkinBioTherapeutics stock, see the GB:SBTX Stock Forecast page.
Spark’s Take on GB:SBTX Stock
According to Spark, TipRanks’ AI Analyst, GB:SBTX is a Neutral.
The score is held back primarily by weak financial performance (ongoing losses and negative operating/free cash flow) despite strong revenue growth and a relatively conservative balance sheet. Technicals are supportive due to positive momentum, but overbought signals temper that strength. Valuation remains challenging because losses make the P/E less meaningful and no dividend yield is available.
To see Spark’s full report on GB:SBTX stock, click here.
More about SkinBioTherapeutics
SkinBioTherapeutics plc is a UK-based life science company focused on skin health, built around its proprietary SkinBiotix® platform developed with the University of Manchester. Its core business targets the skin healthcare market through five pillars, led by cosmetic skincare, delivered via a partnership with Croda under the Zenakine™ brand, and AxisBiotix™ food supplements that leverage the gut-skin axis to address inflammatory skin conditions through direct, online, and high-street retail channels.
The group is also pursuing a consolidation strategy by acquiring complementary skincare and cosmetic businesses that add new distribution channels, geographic reach, and manufacturing capacity for its in-house product pillars. SkinBioTherapeutics listed on AIM in April 2017 and is headquartered in Newcastle, positioning itself as an integrated player across active skincare ingredients, supplements, and broader dermatological applications.
Average Trading Volume: 1,311,568
Technical Sentiment Signal: Buy
Current Market Cap: £51.13M
See more data about SBTX stock on TipRanks’ Stock Analysis page.